Line 34: |
Line 34: |
| ==Additional Information== | | ==Additional Information== |
| | | |
− | *''ANKRD26 (OMIM: [https://omim.org/entry/610855 610855])'' has been associated with thrombocytopenia 2 (OMIM: [https://www.omim.org/entry/188000 188000]) | + | *ANKRD26 (OMIM: [https://omim.org/entry/610855 610855]) has been associated with thrombocytopenia 2 (OMIM: [https://www.omim.org/entry/188000 188000]) |
− | *''CEBPA (OMIM: [https://omim.org/entry/116897 116897])'' has been associated with acute myeloid leukemia (OMIM: [https://www.omim.org/entry/601626 601626]) | + | *CEBPA (OMIM: [https://omim.org/entry/116897 116897]) has been associated with acute myeloid leukemia (OMIM: [https://www.omim.org/entry/601626 601626]) |
− | *''DDX41'' ''(OMIM: 608170)'' has been associated with susceptibility to multiple types of familial myeloproliferative/lymphoproliferative neoplasms (OMIM: [https://www.omim.org/entry/616871 616871]) | + | *DDX41 (OMIM: 608170) has been associated with susceptibility to multiple types of familial myeloproliferative/lymphoproliferative neoplasms (OMIM: [https://www.omim.org/entry/616871 616871]) |
− | *''ETV6'' ''(OMIM: [https://omim.org/entry/600618 600618])'' has been associated with thrombocytopenia 5 (OMIM: [https://www.omim.org/entry/616216 616216]) | + | *ETV6 (OMIM: [https://omim.org/entry/600618 600618]) has been associated with thrombocytopenia 5 (OMIM: [https://www.omim.org/entry/616216 616216]) |
− | *''GATA2 (OMIM: [https://omim.org/entry/137295 137295])'' has been associated with susceptibility to acute myeloid leukemia (OMIM: [https://www.omim.org/entry/601626 601626]) | + | *GATA2 (OMIM: [https://omim.org/entry/137295 137295]) has been associated with susceptibility to acute myeloid leukemia (OMIM: [https://www.omim.org/entry/601626 601626]) |
− | *''RUNX1'' ''(OMIM: [https://omim.org/entry/151385 151385])'' has been associated with acute myeloid leukemia (OMIM: [https://www.omim.org/entry/601626 601626]) and familial platelet disorder with associated myeloid malignancy (OMIM: [https://www.omim.org/entry/601399 601399]) | + | *RUNX1 (OMIM: [https://omim.org/entry/151385 151385]) has been associated with acute myeloid leukemia (OMIM: [https://www.omim.org/entry/601626 601626]) and familial platelet disorder with associated myeloid malignancy (OMIM: [https://www.omim.org/entry/601399 601399]) |
− | *''SAMD9'' ''(OMIM: [https://omim.org/entry/610456 610456])'' has been associated with Myelodysplasia, Infection, Restriction of growth, Adrenal hypoplasia, Genital phenotypes, and Enteropathy (MIRAGE syndrome, (OMIM: [https://www.omim.org/entry/617053 617053]) | + | *SAMD9 (OMIM: [https://omim.org/entry/610456 610456]) has been associated with Myelodysplasia, Infection, Restriction of growth, Adrenal hypoplasia, Genital phenotypes, and Enteropathy (MIRAGE syndrome, (OMIM: [https://www.omim.org/entry/617053 617053]) |
− | *''SAMD9L'' ''(OMIM: [https://omim.org/entry/611170 611170])'' has been associated with ataxia-pancytopenia syndrome, or myelocerebellar disorder, ataxia-pancytopenia syndrome (OMIM: [https://www.omim.org/entry/159550 159550]) | + | *SAMD9L (OMIM: [https://omim.org/entry/611170 611170]) has been associated with ataxia-pancytopenia syndrome, or myelocerebellar disorder, ataxia-pancytopenia syndrome (OMIM: [https://www.omim.org/entry/159550 159550]) |
− | *''SRP72'' ''(OMIM: [https://omim.org/entry/602122 602122])'' has been associated with bone marrow failure syndrome 1 (OMIM: [https://www.omim.org/entry/614675 614675]) | + | *SRP72 (OMIM: [https://omim.org/entry/602122 602122]) has been associated with bone marrow failure syndrome 1 (OMIM: [https://www.omim.org/entry/614675 614675]) |
− | *''TP53'' ''(OMIM: [https://omim.org/entry/191170 191170])'' has been associated with Li-Fraumeni syndrome (OMIM: [https://www.omim.org/entry/151623 151623]) | + | *TP53 (OMIM: [https://omim.org/entry/191170 191170]) has been associated with Li-Fraumeni syndrome (OMIM: [https://www.omim.org/entry/151623 151623]) |
− | *''BLM'' ''(OMIM: [https://omim.org/entry/604610 604610])'' has been associated with Bloom syndrome (OMIM: [https://www.omim.org/entry/210900 210900]) | + | *BLM (OMIM: [https://omim.org/entry/604610 604610]) has been associated with Bloom syndrome (OMIM: [https://www.omim.org/entry/210900 210900]) |
| *Constitutional mismatch repair deficiency (OMIM: [https://www.omim.org/entry/276300 276300]) | | *Constitutional mismatch repair deficiency (OMIM: [https://www.omim.org/entry/276300 276300]) |
| *Neurofibromatosis type I (NF1, OMIM: [https://www.omim.org/entry/162200 162200]) | | *Neurofibromatosis type I (NF1, OMIM: [https://www.omim.org/entry/162200 162200]) |
Line 52: |
Line 52: |
| *Dyskeratosis congenital (DC, please see Genetic heterogeneity of dyskeratosis congenital at OMIM: [https://www.omim.org/entry/127550 127550]) | | *Dyskeratosis congenital (DC, please see Genetic heterogeneity of dyskeratosis congenital at OMIM: [https://www.omim.org/entry/127550 127550]) |
| *Severe congenital neutropenia (SCN, please see Genetic heterogeneity of severe congenital neutropenia at OMIM; [https://www.omim.org/entry/202700 202700]) | | *Severe congenital neutropenia (SCN, please see Genetic heterogeneity of severe congenital neutropenia at OMIM; [https://www.omim.org/entry/202700 202700]) |
− | *Shwachman-Diamond syndrome 1 (SDS1, OMIM: 260400) , <nowiki>https://www.omim.org/entry/260400</nowiki>) and Shwachman-Diamond syndrome 2 (SDS2, OMIM: [https://www.omim.org/entry/617941 617941]) | + | *Shwachman-Diamond syndrome 1 (SDS1, OMIM: [https://www.omim.org/entry/260400 260400]) and Shwachman-Diamond syndrome 2 (SDS2, OMIM: [https://www.omim.org/entry/617941 617941]) |
| *Diamond Blackfan anemia (DBA, please see Genetic heterogeneity of Diamond Blackfan anemia at OMIM: [https://www.omim.org/entry/105650 105650]) | | *Diamond Blackfan anemia (DBA, please see Genetic heterogeneity of Diamond Blackfan anemia at OMIM: [https://www.omim.org/entry/105650 105650]) |
| | | |